An interesting finding of our study, however, is that the effect of extended aromatase inhibition on adapted disease-free survival differed between patients with tumours expressing both the oestrogen and progesterone receptor and patients with tumours expressing only one hormone receptor. This evidence concerns the gene CYP19A1 and neoplasm.